Discovery Laboratories, Inc. (NASDAQ:DSCO)

CAPS Rating: 3 out of 5

A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.

Results 1 - 20 of 69 : 1 2 3 4 Next »

Recs

0
Member Avatar dividendum (< 20) Submitted: 3/14/2014 12:25:48 PM : Outperform Start Price: $2.24 DSCO Score: -32.61

The biotechnology field is on the rise. Big things are to come.

Recs

1
Member Avatar grahamfordummies (61.64) Submitted: 12/30/2013 3:54:45 PM : Outperform Start Price: $2.26 DSCO Score: -33.94

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.

Recs

2
Member Avatar zzlangerhans (99.67) Submitted: 10/16/2013 7:50:45 AM : Outperform Start Price: $2.36 DSCO Score: -45.38

Lots of retail types seem to like playing with Discovery Labs, but after seven years of following the stock I can only recommend it to the traders who are watching the ticker from 7AM-7PM five days a week. Despite the Surfaxin asset, Discovery knows how to put you in the red and when it finally reverses downward momentum, the move never lasts long. And I mean minutes, not hours or days. It must suck to get on the computer at 9AM and find out that the gap up that made your trade profitable came and went an hour ago, and you're back underwater for the next six months.

Discovery has predictably retreated from the recent high after the latest "approval" of Surfaxin. Has it stabilized or will it dive below 2 again? My green thumbs on this stub always go negative, sometimes irretrievably. The next positive catalyst is likely to be the first commercial sale of Surfaxin, a psychological milestone but also the trigger that releases the final 20M tranche of debt financing from Deerfield if it occurs before the end of 2013. It seems like a no-brainer that Discovery would be able to sell one vial of Surfaxin over the next two and a half months, having received final FDA clearance. With this stock, however, logic and reason often lead to disaster and if the next move ends up being yet another below market dilutive financing, traders will have no one to blame but themselves.

Recs

1
Member Avatar toegar2000 (49.55) Submitted: 3/2/2013 10:26:16 AM : Outperform Start Price: $2.43 DSCO Score: -61.72

Looks good

Recs

2
Member Avatar Momentum21 (94.04) Submitted: 3/16/2012 3:12:09 PM : Outperform Start Price: $2.81 DSCO Score: -81.70

Felt it was a good time to close and re-open. Started adding back shares at 2.85 now that the dilution has arrived. This doesn't have the same speculative potential at these levels but I also don't feel that the risk is what it once was...they do have a product to sell now and other products in the pipeline to push along as well...

Climb on my little DSCO...Climb on!

Recs

2
Member Avatar outoffocus (22.87) Submitted: 3/10/2012 12:45:44 PM : Outperform Start Price: $3.65 DSCO Score: -97.99

Biotech watchlist

Recs

2
Member Avatar Sbo2beme (41.00) Submitted: 3/6/2012 5:26:01 PM : Outperform Start Price: $5.24 DSCO Score: -114.43

I think JNJ will buy this stock

Recs

0
Member Avatar OwnTheSector (< 20) Submitted: 3/5/2012 10:53:30 AM : Underperform Start Price: $3.60 DSCO Score: +98.39

FDA gamble.

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 3/3/2012 7:39:37 PM : Outperform Start Price: $2.41 DSCO Score: -80.86

likely fda approval, plenty of time for the company to get the manufacturing issue out of the way.

Recs

1
Member Avatar schuured (97.43) Submitted: 12/6/2011 10:57:14 AM : Outperform Start Price: $2.15 DSCO Score: -70.51

Completely speculative.

Recs

3
Member Avatar californiasun (57.90) Submitted: 8/24/2011 12:18:10 PM : Underperform Start Price: $1.99 DSCO Score: +86.41

History always seems to repeats itself...

Recs

2
Member Avatar calisurfer19 (47.31) Submitted: 6/29/2011 7:30:55 AM : Outperform Start Price: $2.17 DSCO Score: -75.07

Riding out the storm till patent is approved or not.

Recs

0
Member Avatar bearsniper (< 20) Submitted: 4/29/2011 2:17:06 PM : Outperform Start Price: $2.00 DSCO Score: -61.66

Should go higher now that Porte has capitulated! Seems that small biotech has taken the interest of the big boys with recent increases in price and volume.

Recs

2
Member Avatar D0min0 (57.43) Submitted: 4/5/2011 10:43:03 AM : Outperform Start Price: $1.49 DSCO Score: -51.10

FDA approval of its major drug Surfaxin will push share price to at least 10.

Recs

0
Member Avatar rangarajud (45.93) Submitted: 4/2/2011 10:11:29 AM : Outperform Start Price: $1.88 DSCO Score: -59.60

DSCO has comeout with a positive outlook during the last couple of weeks. The trend looks to be positive since they have currently completed batch 1 of trials and are waiting to complete the remaining 3 batches which will be sufficient enough to fulfill the needs of the FDA. The outlook looks promising enough with the financials too since they have a positive cash flow and are ready to submit to the FDA in early third quarter. With all this components which adds up to a successful progression towards the completion of FDA needs and requirements. My Target will be $10 to $12 before the early fouth quarter and then rise upto to $25 to $35 after the approval. ( which will still be about a $1.7 to $2 before the reverse split. )

Recs

4
Member Avatar chimpcontest (< 20) Submitted: 2/21/2011 1:27:25 PM : Outperform Start Price: $2.18 DSCO Score: -72.10

Momentum21 haiku

Disco is not dead

The FDA has it wrong

Rise up from the ash

Recs

0
Member Avatar altutone (< 20) Submitted: 2/20/2011 1:26:33 AM : Outperform Start Price: $2.18 DSCO Score: -72.10

close to " yl" price this is a bargain price and undervalued.

Recs

0
Member Avatar caradeporra (49.59) Submitted: 2/17/2011 3:37:48 PM : Outperform Start Price: $2.19 DSCO Score: -71.06

This is a swing for the fences. Hope it goes up as they get closer to FDA decision. Do you hang on for the ride up or down after the decision comes? Only buy with money you can spare because this one could go either way.

Recs

0
Member Avatar BuildingWings (< 20) Submitted: 2/17/2011 3:24:01 PM : Outperform Start Price: $2.19 DSCO Score: -71.07

Here we go....adding some to my real money portfolio.

Recs

0
Member Avatar t0bes (< 20) Submitted: 2/16/2011 11:55:55 AM : Outperform Start Price: $2.15 DSCO Score: -70.34

bouncing along

Results 1 - 20 of 69 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement